

Examiner's Amendments to the Claims:

Claims 45, 47 and 50 have been amended as follows:

45. (Currently amended) A peptide or polypeptide obtained from the armadillo domain of human β-catenin polypeptide which inhibits the interaction of human β-catenin polypeptide and a transcription factor or tumor suppressor protein, wherein said peptide or polypeptide is selected from the group consisting of peptides or polypeptides consisting of the sequences shown in SEQ ID NO: 6 having a mutation in Phe in position 30, or a mutation in His in ~~position 37~~ position 37 or both; SEQ ID NO: 7 having a mutation in Arg in position 9, or a mutation in Lys in position 27 or both; SEQ ID NO: 8 having a mutation in Trp in position 32, or a mutation in Arg in position 36, or a mutation in Lys in position 39 or any combination of mutations thereof; SEQ ID NO: 9 having a mutation in Lys in position 5, or a mutation in ~~Trp~~ Trp in position 34, or a mutation in Arg in position 37 or any combination of mutations thereof; SEQ ID NO: 10 having a mutation in Lys in position 4; and SEQ ID NO: 11 having a mutation in Lys in position 6, or a mutation in Arg in position 28, or a mutation in Arg in position 40, or a mutation in His in position 41 or any combination of mutations thereof, wherein said mutation replaces the indicated amino acid with an aliphatic amino acid.

47. (Currently amended) The peptide or polypeptide according to claim 44 45, wherein said mutation replaces the indicated amino acid with alanine, valine, leucine or isoleucine.

50. (Currently amended) The peptide of claim 47, wherein ~~the effect is to inhibit the~~

Art Unit: 1653

~~interaction of β-catenin and said transcription factor or tumor suppressor protein is selected from the group consisting of lymphoid enhancer-binding factor-1 (LEF-1), T cell transcription factor-1 (TCF-1), 15 amino acid repeats of adenomatous polyposis coli 15 (APC-15), conductin, E-cadherin and 20 amino acid repeats of APC (APC-20).~~